Molecular Pathology of Gastrointestinal Stromal Tumors and Implications for Treatment and Prognosis

Current Problems in Cancer

Volumn 35, Issue 5, 2011, Pages 245-254

  Parkin, Brian ^a   Chugh, Rashmi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER SURVIVAL; CANCER THERAPY; DISEASE SEVERITY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MITOSIS; MOLECULAR PATHOLOGY; PHENOTYPE; PROGNOSIS; PROTEIN DOMAIN; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT RESPONSE;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 82255193087     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2011.10.002     Document Type: Article

References (43)

1. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
2. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000, 156(3):791-795.
3. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21(23):4342-4349.
4. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
5. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23(23):5357-5364.
6. Pasini B., McWhinney S.R., Bei T., et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16(1):79-88.
7. Matyakhina L., Bei T.A., McWhinney S.R., et al. Genetics of Carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007, 92(8):2938-2943.
8. Janeway K.A., Kim S.Y., Lodish M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011, 108(1):314-318.
9. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105(24):8387-8392.
10. Pantaleo M.A., Astolfi A., Di Battista M., et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer 2009, 125(12):2991-2994.
11. Pantaleo M.A., Astolfi A., Nannini M., et al. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med 2010, 8(1):117.
12. Friedrich R.E., Keiner D., Hagel C. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1. Anticancer Res 2007, 27(4A):2085-2090.
13. Fletcher C.D.M., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002, 10:81-89.
14. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999, 23(1):82-87.
15. Huang H.Y., Li C.F., Huang W.W., et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007, 141(6):748-756.
16. Miettinen M., Sobin L.H., Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005, 29(1):52-68.
17. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006, 30(4):477-489.
18. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23(2):70-83.
19. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002, 20(18):3898-3905.
20. Kim T.W., Lee H., Kang Y.K., et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004, 10(9):3076-3081.
21. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59(17):4297-4300.
22. Ernst S.I., Hubbs A.E., Przygodzki R.M., et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998, 78(12):1633-1636.
23. Martín J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005, 23(25):6190-6198.
24. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003, 9(9):3329-3337.
25. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84(7):874-883.
26. Lasota J., Stachura J., Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006, 86(1):94-100.
27. Hostein I., Debiec-Rychter M., Olschwang S., et al. A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours. J Gastroenterol 2011, 46(5):586-594.
28. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
29. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42(8):1093-1103.
30. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase S0033. J Clin Oncol 2008, 26(4):626-632.
31. Heinrich M.C., Owzar K., Corless C.L., et al. Correlation of kinase genotype and clinical outcome in the North American InterGroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008, 26(33):5360-5367.
32. Gramza A.W., Corless C.L., Heinrich M.C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009, 15(24):7510-7518.
33. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24(29):4764-4774.
34. Shankar S., vanSonnenberg E., Desai J., et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005, 235(3):892-898.
35. Desai J., Shankar S., Heinrich M.C., et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007, 13(18 Pt 1):5398-5405.
36. Gounder M.M., Maki R.G. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011, 67(Suppl 1):S25-S43.
37. Wang W.L., Conley A., Reynoso D., et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011, 67(Suppl 1):S15-S24.
38. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12(6):1743-1749.
39. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11(11):4182-4190.
40. Liegl B., Kepten I., Le C., et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216(1):64-74.
41. Miselli F.C., Casieri P., Negri T., et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res 2007, 13(8):2369-2377.
42. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47(10):853-859.
43. Mahadevan D., Cooke L., Riley C., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007, 26(27):3909-3919.